TY - JOUR
T1 - Molecular pathways
T2 - Dysregulated glutamatergic signaling pathways in cancer
AU - Prickett, TD
AU - Samuels, Yardena
N1 - National Human Genome Research Institute, National Institutes of Health Intramural Research Program, National Human Genome Research Institute, National Institutes of Health.
PY - 2012/8/15
Y1 - 2012/8/15
N2 - The neurotransmitter glutamate interacts with glutamate receptor proteins, leading to the activation of multiple signaling pathways. Dysfunction in the glutamatergic signaling pathway is well established as a frequent player in diseases such as schizophrenia, Alzheimer disease, and brain tumors (gliomas). Recently, aberrant functioning of this pathway has also been shown in melanoma. In both glioma and melanoma, glutamate secretion stimulates tumor growth, proliferation, and survival through activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase/Akt pathways. In the future, extracellular glutamate levels and glutamatergic signaling may serve as biological markers for tumorigenicity and facilitate targeted therapy for melanoma.
AB - The neurotransmitter glutamate interacts with glutamate receptor proteins, leading to the activation of multiple signaling pathways. Dysfunction in the glutamatergic signaling pathway is well established as a frequent player in diseases such as schizophrenia, Alzheimer disease, and brain tumors (gliomas). Recently, aberrant functioning of this pathway has also been shown in melanoma. In both glioma and melanoma, glutamate secretion stimulates tumor growth, proliferation, and survival through activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase/Akt pathways. In the future, extracellular glutamate levels and glutamatergic signaling may serve as biological markers for tumorigenicity and facilitate targeted therapy for melanoma.
UR - http://www.scopus.com/inward/record.url?scp=84865069757&partnerID=8YFLogxK
U2 - https://doi.org/10.1158/1078-0432.CCR-11-1217
DO - https://doi.org/10.1158/1078-0432.CCR-11-1217
M3 - مقالة مرجعية
SN - 1078-0432
VL - 18
SP - 4240
EP - 4246
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 16
ER -